Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novo Nordisk is opening an R&D center in Seattle dedicated to accelerating the development of new treatments for type 1 diabetes. Slated to open this summer with about 20 scientists, the center will bring together at one site basic research and early proof-of-concept trials. Novo says this approach will enable new therapies to move quickly from animal models into human tests. Matthias von Herrath, currently director of the Center for Type 1 Diabetes Research at La Jolla Institute for Allergy & Immunology, will head the new center.
This article has been sent to the following recipient: